TVTX Travere Therapeutics, Inc.
FY2025 10-K
Travere Therapeutics, Inc. (TVTX) filed its fiscal year 2025 10-K annual report with the SEC on Feb 19, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Developing, manufacturing outsourced, and commercializing pharmaceutical products, including marketed drug FILSPARI and pipeline candidates
- • New emphasis on pegtibatinase Phase 3 HARMONY Study resumed in 2026 after voluntary enrollment pause in Sept 2024 due to manufacturing scale-up issues
Management Discussion & Analysis
- • Revenue specifics and YoY changes not disclosed in provided MD&A section
- • Profitability or margin figures absent; no actual % margins reported
Risk Factors
- • Cybersecurity risk management overseen by Nominating / Corporate Governance Committee reporting to board
- • Cybersecurity incident team with cross-functional expertise including IT, legal, compliance, and privacy functions
Financial SummaryXBRL
Revenue
$491M
Net Income
-$26M
Operating Margin
-12.8%
Net Margin
-5.2%
ROE
-22.2%
Total Assets
$605M
EPS (Diluted)
$-0.29
Operating Cash Flow
$38M
Source: XBRL data from Travere Therapeutics, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Travere Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.